Personalised melanoma vaccine reduces recurrence risk in phase 3 trial
Published on 29 October 2026 at 01:55 GMT
By Editorial Team SDG3
A personalised melanoma vaccine has reduced the risk of recurrence or death when added to immunotherapy after surgery, according to detailed phase 3 results announced by Moderna and Merck on 22 October 2026. The experimental treatment, intismeran autogene, remains under investigation. An improvement in overall survival has not yet been established.
The companies reported a 42% reduction in the hazard of recurrence or death compared with pembrolizumab alone, after median follow-up of 24.6 months (hazard ratio 0.58; 95% confidence interval 0.45 to 0.75). This combined endpoint does not establish a 42% reduction in deaths alone or mean that 42% of patients were cured. Overall survival data remain immature, and follow-up continues.
What the trial tested
INTerpath-001 compares intismeran plus pembrolizumab with placebo plus pembrolizumab after complete surgical removal of high-risk melanoma. Its registration on ClinicalTrials.gov identifies a randomised, double-blind, placebo- and active-comparator-controlled phase 3 study. The question is whether adding the personalised treatment improves outcomes beyond those achieved with the existing immunotherapy.
Random allocation creates comparison groups without patients choosing their treatment arm. The placebo provides a comparison for the added vaccine, while pembrolizumab is present in both groups. This design therefore tests the additional contribution of intismeran in that treatment setting. It does not compare vaccination alone with surgery alone, and cannot establish that the vaccine replaces the other treatment.
The registered eligibility criteria specify completely resected stage IIB, IIC, III or IV cutaneous melanoma. Evidence from people treated after surgery does not establish effectiveness in other cancers, in every melanoma stage or in people whose cancer cannot be surgically removed.
A treatment vaccine rather than routine prevention
The National Cancer Institute distinguishes therapeutic cancer vaccines from vaccines that prevent infections associated with cancer. Treatment vaccines work against cancer cells in people who have cancer. Their purpose is to help the immune system recognise relevant antigens and respond to cells carrying them, rather than prevent an infectious disease before it occurs.
The institute describes several approaches, including vaccines made using a person's tumour cells and vaccines directed at antigens shared across patients. Intismeran is an mRNA treatment designed using the mutational signature of each patient's tumour, according to its developers. Personalisation alone does not establish whether an individual patient will benefit.
Cancer vaccines are also a broader category than this particular mRNA candidate. The institute lists the approved dendritic-cell treatment sipuleucel-T for certain prostate cancers and describes the oncolytic virus treatment T-VEC, used for some melanomas, as another approach sometimes called a cancer treatment vaccine. These are different products with different uses. Their existence does not confer approval on intismeran.
Why combine it with immunotherapy
Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. As the National Cancer Institute explains, checkpoints normally restrain immune responses and help protect healthy cells. Cancer can exploit these signals, preventing immune cells called T cells from attacking tumour cells. Checkpoint inhibitors interfere with that signalling, allowing an immune response against cancer.
The combination brings together two immunotherapy functions: directing recognition towards cancer-associated targets and reducing an inhibitory signal. That biological rationale explains the research question, but the trial comparison supplies the evidence about outcomes. A plausible mechanism and an observed clinical benefit are distinct forms of evidence.
Checkpoint inhibition also carries risks. The institute lists rash, diarrhoea and fatigue among common side effects, with less common inflammatory effects potentially involving organs such as the lungs, liver, heart, kidneys and endocrine glands. Treatment vaccines can also cause side effects, including fever and fatigue. Combining immune treatments is therefore evaluated for safety as well as cancer control.
The companies reported grade 3-5 treatment-related adverse events in 14.2% of patients receiving the combination and 13.4% receiving pembrolizumab alone. These aggregate figures describe trial groups. They do not establish that every patient experiences the same burden or that uncommon harms are absent.
Recurrence and survival answer different questions
The National Cancer Institute defines overall survival in terms of remaining alive over a specified period, irrespective of cause of death. Disease-free survival concerns the absence of signs of cancer during a defined period after treatment. The precise endpoint definition in an individual trial determines which events are counted and when observation begins.
A recurrence endpoint can register a cancer returning while a patient remains alive. Overall survival records a different outcome. Consequently, a reduction in a composite of recurrence or death cannot be relabelled as a proven reduction in mortality. The distinction is relevant to patients weighing what an announcement establishes about living without recurrence and what it establishes about living longer.
The institute also cautions that survival statistics describe groups and cannot predict exactly what will happen to an individual. Prognosis depends on factors including cancer stage, biological characteristics, health before treatment and response to therapy. A trial result informs that discussion without supplying a personal guarantee.
According to the companies’ announcement, intismeran improved recurrence-free survival in the studied postoperative setting. Whether that improvement translates into longer overall survival remains an unanswered clinical question.
Written by a human author, edited with AI assistance.
Further information:
* Merck, the 22 October 2026 announcement supplies the phase 3 efficacy findings, follow-up, experimental status and reported safety comparison.
* ClinicalTrials.gov, study NCT05933577 documents the registered trial design, treatment comparison and postoperative melanoma setting.
* National Cancer Institute, Cancer Treatment Vaccines explains therapeutic vaccination, different vaccine approaches and possible side effects.
* National Cancer Institute, Immune Checkpoint Inhibitors explains checkpoint signalling and the adverse effects of this treatment class.
* National Cancer Institute, Understanding Cancer Prognosis explains survival measures and the limits of applying group statistics to individuals.
